Premium
In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs
Author(s) -
Tay S. T.,
Tanty Haryanty T.,
Ng K. P.,
Rohani M.Y.,
Hamimah H.
Publication year - 2006
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2006.01242.x
Subject(s) - flucytosine , cryptococcus gattii , itraconazole , cryptococcus neoformans , ketoconazole , fluconazole , cryptococcus , amphotericin b , microbiology and biotechnology , cryptococcosis , biology , etest , antifungal , antibiotics
Summary The in vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and C . gattii to five antifungal drugs (amphotericin B, flucytosine, fluconazole, itraconazole and ketoconazole) were determined using the Etest method. None of the Malaysian isolates was resistant to amphotericin B and ketoconazole. Isolates resistant to flucytosine, fluconazole and itraconazole were observed in this study. Minimum inhibition concentrations (MICs) of ≥32 μ g ml −1 against flucytosine, ≥64 μ g ml −1 against fluconazole and ≥1 μ g ml −1 against itraconazole were noted in four (8.3%), two (4.2%) and one (2.1%) isolates respectively. There was no significant difference in the MICs for both Cryptococcus species ( P > 0.05), indicating that C. gattii was as susceptible as var. grubii to all the antifungal drugs tested. No significant difference in the MICs for both Cryptococcus species collected from 1980 to 1990 and 2002 to 2004 were observed ( P > 0.05).